DATA + PERSPECTIVES
Clinical Investigators Explore the Current and Future Management of HER2-Positive Breast Cancer

Friday, December 13, 2019
7:30 PM – 9:00 PM
San Antonio, Texas

Moderator
Neil Love, MD

Faculty
Adam M Brufsky, MD, PhD
Lisa A Carey, MD
Sara Hurvitz, MD
Martine J Piccart-Gebhart, MD, PhD
Disclosures for Moderator Neil Love, MD

Agenda

**Module 1 – Dr Carey:** Considerations in the Care of Patients with Localized HER2-Positive Breast Cancer (BC) Receiving Neoadjuvant Systemic Therapy

**Module 2 – Prof Piccart-Gebhart:** Adjuvant and Extended-Adjuvant Therapy for Patients with Localized HER2-Positive BC

**Module 3 – Dr Brufsky:** Available Therapeutic Options for the Management of HER2-Positive Metastatic BC (mBC)

**Module 4 – Dr Hurvitz:** Novel Agents and Strategies Under Evaluation for Patients with HER2-Positive mBC
The Second Annual
Miami General Medical Oncology Symposium

February 21-23, 2020
JW Marriott Miami Turnberry
Miami, Florida
Dr. Bernard Fisher, Who Revolutionized Breast Cancer Treatment, Dies at 101
DATA + PERSPECTIVES
Clinical Investigators Explore the Current and Future Management of HER2-Positive Breast Cancer

Friday, December 13, 2019
7:30 PM – 9:00 PM
San Antonio, Texas

Moderator
Neil Love, MD

Faculty
Adam M Brufsky, MD, PhD
Lisa A Carey, MD
Sara Hurvitz, MD
Martine J Piccart-Gebhart, MD, PhD
HR-positive, HER2-positive
2 positive nodes

- 70 people cancer free: no further treatment
- 15 people cancer free: chemotherapy/trastuzumab
- 2 more people cancer free by adding pertuzumab
- 2 more people cancer free by adding postadjuvant neratinib
- 11 people: cancer recurrence

Estimates provided to patients by 30 breast cancer clinical investigators